Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

A likelihood estimation of HIV incidence incorporating information on past prevalence.

Gabaitiri L, Mwambi HG, Lagakos SW, Pagano M.

S Afr Stat J. 2013 Mar;47(1):15-31.

2.

Statistical considerations when using a composite endpoint for comparing treatment groups.

Gómez G, Lagakos SW.

Stat Med. 2013 Feb 28;32(5):719-38. doi: 10.1002/sim.5547. Epub 2012 Aug 1.

PMID:
22855368
3.

Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis.

Becquet R, Marston M, Dabis F, Moulton LH, Gray G, Coovadia HM, Essex M, Ekouevi DK, Jackson D, Coutsoudis A, Kilewo C, Leroy V, Wiktor SZ, Nduati R, Msellati P, Zaba B, Ghys PD, Newell ML; UNAIDS Child Survival Group.

PLoS One. 2012;7(2):e28510. doi: 10.1371/journal.pone.0028510. Epub 2012 Feb 23.

4.

Testing and interval estimation for two-sample survival comparisons with small sample sizes and unequal censoring.

Wang R, Lagakos SW, Gray RJ.

Biostatistics. 2010 Oct;11(4):676-92. doi: 10.1093/biostatistics/kxq021. Epub 2010 May 2.

5.

Inference after variable selection using restricted permutation methods.

Wang R, Lagakos SW.

Can J Stat. 2009 Dec 1;37(4):625-644.

6.

HIV-1 Subtype C Phylodynamics in the Global Epidemic.

Novitsky V, Wang R, Lagakos S, Essex M.

Viruses. 2010 Jan;2(1):33-54. doi: 10.3390/v2010033. Epub 2010 Jan 7.

7.

Augmented cross-sectional prevalence testing for estimating HIV incidence.

Wang R, Lagakos SW.

Biometrics. 2010 Sep;66(3):864-74. doi: 10.1111/j.1541-0420.2009.01356.x.

8.

Timing constraints of in vivo gag mutations during primary HIV-1 subtype C infection.

Novitsky V, Wang R, Margolin L, Baca J, Kebaabetswe L, Rossenkhan R, Bonney C, Herzig M, Nkwe D, Moyo S, Musonda R, Woldegabriel E, van Widenfelt E, Makhema J, Lagakos S, Essex M.

PLoS One. 2009 Nov 5;4(11):e7727. doi: 10.1371/journal.pone.0007727.

9.

On the use of adjusted cross-sectional estimators of HIV incidence.

Wang R, Lagakos SW.

J Acquir Immune Defic Syndr. 2009 Dec;52(5):538-47. doi: 10.1097/QAI.0b013e3181c080a7.

10.

Nonparametric inference and uniqueness for periodically observed progressive disease models.

Griffin BA, Lagakos SW.

Lifetime Data Anal. 2010 Apr;16(2):157-75. doi: 10.1007/s10985-009-9122-8. Epub 2009 Jul 23.

11.

Marginal analysis of panel counts through estimating functions.

Hu XJ, Lagakos SW, Lockhart RA.

Biometrika. 2009;96(2):445-456.

12.

Better control of early viral replication is associated with slower rate of elicited antiviral antibodies in the detuned enzyme immunoassay during primary HIV-1C infection.

Novitsky V, Wang R, Kebaabetswe L, Greenwald J, Rossenkhan R, Moyo S, Musonda R, Woldegabriel E, Lagakos S, Essex M.

J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):265-72. doi: 10.1097/QAI.0b013e3181ab6ef0.

13.

Estimating HIV incidence based on combined prevalence testing.

Balasubramanian R, Lagakos SW.

Biometrics. 2010 Mar;66(1):1-10. doi: 10.1111/j.1541-0420.2009.01242.x. Epub 2009 Apr 13. Erratum in: Biometrics. 2010 Mar;66(1):326.

14.

Viral load and CD4+ T-cell dynamics in primary HIV-1 subtype C infection.

Novitsky V, Woldegabriel E, Kebaabetswe L, Rossenkhan R, Mlotshwa B, Bonney C, Finucane M, Musonda R, Moyo S, Wester C, van Widenfelt E, Makhema J, Lagakos S, Essex M.

J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):65-76. doi: 10.1097/QAI.0b013e3181900141.

15.
16.

Statistical monitoring of clinical trials with multivariate response and/or multiple arms: a flexible approach.

Zhao L, Hu XJ, Lagakos SW.

Biostatistics. 2009 Apr;10(2):310-23. doi: 10.1093/biostatistics/kxn037. Epub 2008 Nov 16.

17.

Evolution of proviral gp120 over the first year of HIV-1 subtype C infection.

Novitsky V, Lagakos S, Herzig M, Bonney C, Kebaabetswe L, Rossenkhan R, Nkwe D, Margolin L, Musonda R, Moyo S, Woldegabriel E, van Widenfelt E, Makhema J, Essex M.

Virology. 2009 Jan 5;383(1):47-59. doi: 10.1016/j.virol.2008.09.017. Epub 2008 Oct 29.

18.

Challenges to HIV prevention--seeking effective measures in the absence of a vaccine.

Lagakos SW, Gable AR.

N Engl J Med. 2008 Apr 10;358(15):1543-5. doi: 10.1056/NEJMp0802028. No abstract available.

19.

Statistics in medicine--reporting of subgroup analyses in clinical trials.

Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM.

N Engl J Med. 2007 Nov 22;357(21):2189-94. No abstract available.

Supplemental Content

Loading ...
Support Center